ReviewClinical cardiology2022
New strategies and therapies for the prevention of heart failure in high-risk patients.
Review in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Opportunities and Challenges of Cardiovascular Disease Risk Prediction for Primary Prevention Using Machine Learning and Electronic Health Records: A Systematic Review.Reviews in cardiovascular medicine · 2025Pooled it
- The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review.ESC heart failure · 2025Pooled it
- Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.European heart journal · 2026Article
- Implementing Orem's Self-Care Model on Health-Promoting Behaviors in Patients with Heart Failure: A Quasi-Experimental Study.Patient preference and adherence · 2026Article
- Rethinking Secondary Cardiovascular Prevention in the Digital Era: Patient Empowerment, Adherence and Optimisation of Guideline-based Care.European cardiology · 2026Review
- The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.American journal of preventive cardiology · 2025Review
- Risk of Progression and Costs of Care for Patients with Type 2 Diabetes and Chronic Kidney Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study.European heart journal · 2025Article
- Multimodal Cardiac Imaging Revisited by Artificial Intelligence: An Innovative Way of Assessment or Just an Aid?Cureus · 2024Review
- Harnessing the potential of mesenchymal stem cells-derived exosomes in degenerative diseases.Regenerative therapy · 2024Review
- Scalable Risk Stratification for Heart Failure Using Artificial Intelligence applied to 12-lead Electrocardiographic Images: A Multinational Study.medRxiv : the preprint server for health sciences · 2024Article
- Early detection of heart failure using in-patient longitudinal electronic health records.PloS one · 2024Article
- Biomarkers for Heart Failure Prediction and Prevention.Journal of cardiovascular development and disease · 2023Review
- New strategies and therapies for the prevention of heart failure in high-risk patients.Clinical cardiology · 2022Review
- Advances in the management of heart failure.Clinical cardiology · 2022Article
- Prioritizing the primary prevention of heart failure: Measuring, modifying and monitoring risk.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite declines in total cardiovascular mortality rates in the United States, heart failure (HF) mortality rates as well as hospitalizations and readmissions have increased in the past decade. Increases have been relatively higher among young and middle-aged adults (<65 years). Therefore, identification of individuals HF at-risk (Stage A) or with pre-HF (Stage B) before the onset of overt clinical signs and symptoms (Stage C) is urgently needed. Multivariate risk models (e.g., Pooled Cohort Equations to Prevent Heart Failure [PCP-HF]) have been externally validated in diverse populations and endorsed by the 2022 HF Guidelines to apply a risk-based framework for the prevention of HF. However, traditional risk factors included in the PCP-HF model only account for half of an individual's lifetime risk of HF; novel risk factors (e.g., adverse pregnancy outcomes, impaired lung health, COVID-19) are emerging as important risk-enhancing factors that need to be accounted for in personalized approaches to prevention. In addition to determining the role of novel risk-enhancing factors, integration of social determinants of health (SDoH) in identifying and addressing HF risk is needed to transform the current clinical paradigm for the prevention of HF. Comprehensive strategies to prevent the progression of HF must incorporate pharmacotherapies (e.g., sodium glucose co-transporter-2 inhibitors that have also been termed the "statins" of HF prevention), intensive blood pressure lowering, and heart-healthy behaviors. Future directions include investigation of novel prediction models leveraging machine learning, integration of risk-enhancing factors and SDoH, and equitable approaches to interventions for risk-based prevention of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.